WhatsAppCurrent scientific evidence is taken into account at the Dr. Resul Yaman Hair Transplant Clinic when it comes to the evaluation of new treatments for androgenetic alopecia. Male pattern hair loss is a progressive, chronic condition due to genetic susceptibility coupled with activity of the androgen hormone.
The treatments have been quite limited over the years. Finasteride and Minoxidil were established until recently as the standard worldwide medical approaches. Recently, however, a new pharmacological option with a different mechanism-the topical solution of Clascoterone 5% has gained mainstream attention.
In this article, we objectively review the scientific background of this local anti-androgen therapy for the first time, along with clinical data and its positioning among current hair loss treatments.
Clascoterone is a topical medication which locally blocks androgen receptors in the skin. In male pattern hair loss, DHT binds to androgen receptors within hair follicles. Over time, this causes thinning of the hair shaft and miniaturization of follicles.
Unlike other treatments, the locally acting anti-androgen agent does not suppress DHT production; it blocks its activities right at the level of follicular receptors. Hence, this may further decrease the risk of systemic hormonal suppression.
Another advantage of this topical androgen receptor blocker is that its active ingredient has already been used at lower dosages in FDA- and EMA-approved acne treatments. Due to this fact, its dermatologic safety profile is considered a major advantage. However, long-term effects of the 5% formulation on the scalp remain under evaluation.
Two large Phase III clinical trials were conducted with Clascoterone 5% topical solution. The research was carried out across multiple centers in the United States and various European countries. In total, there were 1,465 male patients.
Results have shown statistically significant increases in target-area hair counts versus placebo, while the side effect profile has remained comparable to placebo.
Peer-reviewed dermatology journals have variously described Clascoterone as a “next-generation topical antiandrogen”. The majority of these publications also cite limited real-world and long-term data. Therefore, the investigational 5% topical agent remains promising but still needs further clinical observation.
Efficacy studies indicate very minimal absorption, which serves to lower side effects during sex. Real-data studies are very limited in this instance.
Experiences and expectations about Clascoterone 5% are also being discussed by patients with much vigor on platforms like Reddit. Most of the users are cautiously optimistic rather than showing pure enthusiasm.
Some individuals emphasize its local action and low systemic risk profile. Others mention the previous treatments that created high expectations but brought only a little into real life. In general, users express an opinion that the study drug cannot be used as a standalone cure, yet it may serve as a supportive option in selected patients.
Medications developed for androgenetic alopecia are compared in the chart below.
| Treatment | Mechanism of Action | Application | Systemic Effect | FDA Approval |
| Finasteride | Suppresses DHT production | Oral | Yes | Yes |
| Minoxidil | Extends growth phase | Topical | No | Yes |
| Clascoterone 5% | Androgen receptor blockade | Topical | Minimal | No |
| PP405 | Cellular activation (experimental) | Topical | Unknown | No |
The only two drugs physicians prescribe that are approved by the FDA are Finasteride and Minoxidil. On the other hand, Clascoterone 5% and PP405 are not yet approved by the FDA.
Answer: Some doctors suggest a combination of topical therapies, but very less literature is available for a combination of topical therapies.
Answer: Finasteride decreases systemic levels of DHT, and clascoterone acts locally by inhibiting androgen receptors.
Despite the advent of medical therapies, hair replacement remains the most effective means of restoring hair in conditions producing advanced hair loss. Medical therapy may slow the progression or increase density modestly; however, surgery is still the gold standard in the restoration of lost hair.
For this reason, currently, Turkey is unique in the whole world for hair transplant procedures. The country merges experience of physicians with advanced infrastructure in the medical field.
For patients who want to visit the licensed clinics, there is a possibility of visiting the official website of Health Turkiye. On the website, there is a list of clinics and doctors approved by the Ministry of Health. You can also find Dr. Resul Yaman on that platform and detailed clinic information.
Clascoterone 5% topical solution, has scientific interest in managing androgenetic alopecia among males. Clinical data are encouraging, but it is too early to replace established therapies.
Medical treatments may be beneficial when combined with hair plantation. They also may be of benefit in selected groups of patients.
At Dr. Resul Yaman Hair Transplant Clinic, accuracy in information and full transparency are crucial. At the end of the day, a successful hair loss treatment is all about the right patient, at the right time, with the right technique.
Get Mail!